+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ropinirole"

Restless Legs Syndrome - Global Strategic Business Report - Product Thumbnail Image

Restless Legs Syndrome - Global Strategic Business Report

  • Report
  • April 2025
  • 290 Pages
  • Global
From
Anti-Parkinson Drugs Market Report 2025 - Product Thumbnail Image

Anti-Parkinson Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
From
Neuroprotection - Methods, Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Methods, Drugs, Markets and Companies

  • Report
  • November 2021
  • 844 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Ropinirole is a centrally-acting dopamine agonist used to treat Parkinson's disease and restless legs syndrome. It is a non-ergoline dopamine agonist, meaning it does not contain the ergot alkaloid found in some other dopamine agonists. Ropinirole works by stimulating dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease and restless legs syndrome. It is available in both immediate-release and extended-release formulations. Ropinirole is marketed by several pharmaceutical companies, including GlaxoSmithKline, Sun Pharmaceuticals, and Mylan. It is also available as a generic drug in some countries. It is available in tablet, capsule, and oral solution forms. In the market for central nervous system drugs, Ropinirole is a popular choice for treating Parkinson's disease and restless legs syndrome. It is well-tolerated and has a low risk of side effects. It is also relatively inexpensive compared to other dopamine agonists. Companies in the Ropinirole market include GlaxoSmithKline, Sun Pharmaceuticals, Mylan, Teva Pharmaceuticals, and Accord Healthcare. Show Less Read more